bezafibrate has been researched along with Sensitivity and Specificity in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kunkel, U; Radke, M; Riml, J; Wörman, A | 1 |
| Gujer, W; Neumann, MB; von Gunten, U | 1 |
| He, JG; Lu, XH; Lv, GP; Si, SY; Zhang, H; Zhao, BH; Zheng, ZH | 1 |
| Cuniberti, LA; Masnatta, LD; Rey, RH; Werba, JP | 1 |
| Flavell, DM; Hawe, E; Humphries, SE; Jamshidi, Y; MacCallum, PK; Meade, TW | 1 |
| Bar-Tana, J; Hertz, R; Kalderon, B; Shachrur, S; Sheena, V | 1 |
1 trial(s) available for bezafibrate and Sensitivity and Specificity
| Article | Year |
|---|---|
Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein C-III; Apolipoproteins C; Arterial Occlusive Diseases; Base Sequence; Bezafibrate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Genetic Markers; Genetic Predisposition to Disease; Genotype; Humans; Hypolipidemic Agents; Male; Middle Aged; Molecular Sequence Data; Peripheral Vascular Diseases; Polymerase Chain Reaction; Polymorphism, Genetic; Probability; Reference Values; Sensitivity and Specificity; Treatment Outcome | 2002 |
5 other study(ies) available for bezafibrate and Sensitivity and Specificity
| Article | Year |
|---|---|
Evaluating the fate of six common pharmaceuticals using a reactive transport model: insights from a stream tracer test.
Topics: Adsorption; Bezafibrate; Chromatography, High Pressure Liquid; Clofibric Acid; Ibuprofen; Metoprolol; Models, Theoretical; Naproxen; Pharmaceutical Preparations; Rivers; Sensitivity and Specificity; Sweden; Tandem Mass Spectrometry; Water Movements; Water Pollutants, Chemical | 2013 |
Global sensitivity analysis for model-based prediction of oxidative micropollutant transformation during drinking water treatment.
Topics: Bezafibrate; Carcinogens; Ciprofloxacin; Methyl Ethers; Naphthols; Ozone; Predictive Value of Tests; Probability; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Water Pollutants, Chemical; Water Supply | 2009 |
Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.
Topics: Animals; Bezafibrate; Cells, Cultured; Chenodeoxycholic Acid; Drug Discovery; Genetic Vectors; HeLa Cells; High-Throughput Screening Assays; Humans; Hydrocarbons, Fluorinated; Ligands; Mice; NIH 3T3 Cells; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Promoter Regions, Genetic; Pyrimidines; Rosiglitazone; Sensitivity and Specificity; Structure-Activity Relationship; Sulfonamides; Thiazolidinediones; Two-Hybrid System Techniques | 2010 |
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
Topics: Bezafibrate; Calibration; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Reproducibility of Results; Sensitivity and Specificity | 1996 |
Modulation by nutrients and drugs of liver acyl-CoAs analyzed by mass spectrometry.
Topics: Acyl Coenzyme A; Animals; Bezafibrate; Diet; Dietary Fats; Hypolipidemic Agents; Liver; Male; Nafenopin; Palmitic Acids; Rats; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Xenobiotics | 2002 |